California Dreaming: Long-Term Messages From Governor’s Rx Price Actions
Executive Summary
Immediate impact of California Governor Newsom’s directive on drug pricing unlikely to be dramatic, but there are important long-term messages for biopharma companies to weigh.
You may also be interested in...
Outcomes-Based Contracts May Be Negotiated By Michigan Medicaid
Michigan follows Oklahoma in gaining approval to negotiate supplemental rebates in the context of value-based contracts for drugs. Oklahoma now has four novel contracts in place.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.